The use of antiretrovirals as pre-exposure prophylaxis (PrEP) is highly efficacious in HIV 
INTRODUCTION
The use of antiretrovirals (ARVs) as pre-exposure prophylaxis (PrEP) is highly efficacious at limiting HIV transmission [1] [2] [3] [4] [5] [6] [7] . Single-agent TDF PrEP shows benefit over placebo and is comparable with Truvada in preventing HIV transmission in HIV serodiscordant heterosexual couples [2] and individuals who inject drugs [3] . Efficacy data for TDF in men who have sex with men (MSM) are limited [8] and it is not known whether drug level requirements are the same for both HIV treatment and prevention. However, animal model data suggest that TDF alone is less protective than Truvada [9, 10] and pharmacokinetic analysis of the partners PrEP study supports this [11] . Cases of PrEP failure mainly occur due to poor adherence [1] [2] [3] [4] [5] [6] 11] . Early detection is essential to minimize monotherapy drug exposure and prevent drug resistance development [12] . Whether ARV therapy (ART) should be stopped or intensified at PrEP failure is unclear [13] . A recent case presentation reported an undetectable viral reservoir in an individual's intensifying ART at PrEP failure [14] . This is supported by cohort data and data from macaques suggest that three-drug ARV at acute HIV infection can improve clinical outcome [15] [16] [17] by limiting viral reservoir [17] [18] [19] [20] and immune dysfunction [21] [22] [23] , and that these benefits are greater the earlier the ARVs are started [15] [16] [17] .
We Table 1 . The tenofovir concentration for each patient was plotted against a percentile plot derived from a published population pharmacokinetic model of tenofovir plasma concentrations in HIV-infected subjects (Fig. 1 ) [25] . ART antiretroviral therapy, EDSC estimated date of HIV seroconversion, TDF tenofovir disoproxil fumarate, VL viral load
Laboratory Results

Patient
HIV Reservoir
Purified CD4 T cells were analyzed by qPCR for HIV-1 DNA (total and integrated) and cell-associated HIV-1 RNA unspliced transcripts (CA-RNA) as reported elsewhere [19] .
Immune Activation and Exhaustion
PBMC were stained with the anchor markers 
DISCUSSION
As PrEP is becoming more widely available and uptake increasing, this is a timely reminder that TDF monotherapy PrEP in MSM has limited efficacy data and that HIV-1 acquisition can occur in the presence of TFV drug levels within the therapeutic range required to treat HIV [26] .
These cases are instructive to providers and the field of PrEP, and highlight that patients with HBV receiving tenofovir for HBV should consider intensification to Truvada (TDF/FTC) if they meet guidelines (e.g., Centers for Disease Control and Prevention) for PrEP. The lack of resistance detected concurs with randomized control study data showing a very low incidence of resistance in cases of tenofovir failure [29] . Although PrEP effectiveness is largely driven by adherence [1-8, 11, 26, 27 
CONCLUSION
Single-drug TDF PrEP was not effective in preventing HIV infection and intensified ART post-infection did not reduce the viral reservoir in either patient. Whilst single-agent PrEP is not to be recommended as an HIV prevention strategy in MSM in European [28] and US [13] PrEP guidelines, it is by the WHO [7] . Close monitoring of outcomes of TDF usage in MSM needs to be carried out.
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